valsartan / Generic mfg. - LARVOL DELTA

Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus. (PubMed, J Hum Hypertens) - "Secondary analyses were also not significantly different. Overall, this study did not detect sufficient evidence that telmisartan reduces NODM risk compared with losartan, valsartan, or candesartan."

Journal • Diabetes • Metabolic Disorders • PPARG

Differentiating therapeutic use and potential impairment in the forensic interpretation of valsartan concentrations in road traffic offenders. (PubMed, Int J Legal Med) - "The case of a 59‑year‑old male who experienced a medical incident while driving enabled the identification of a valsartan concentration of 12.7 µg/mL, which was well above the expected range. Potential interactions with concomitantly administered medications are also considered."

Journal • Cardiovascular

Isolated Collagenous Gastritis With Biopsy-Confirmed Histologic Resolution Following Etodolac Cessation in an Adult With Psoriatic Arthritis and Atopic Diathesis (ACG 2026) - "Medication included chronic daily etodolac, adalimumab, and valsartan...An empiric 8-week course of pantoprazole 40mg twice daily failed to improve symptoms...Without an identifiable etiology, etodolac was discontinued, and therapy was transitioned to omeprazole 40mg twice daily...(A) Initial evaluation demonstrating diffuse moderate inflammation with erythema, edema, erosions, and friability of the gastric body. (B) Follow-up endoscopy after etodolac cessation showed a more uniform mucosal surface with reduced erythema and fewer erosive changes."

Biopsy • Clinical • Allergic Rhinitis • Atopic Dermatitis • Celiac Disease • Dermatitis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Angiotensin II-driven TGF-β1 increases platelet PAR4 expression enhancing thrombotic risk in hypertension. (PubMed, Eur Heart J) - "Angiotensin Ⅱ-driven TGF-β1 upregulates platelet PAR4 transcription to enhance platelet activation in hypertension. Valsartan reverses platelet PAR4 overexpression to inhibit thrombus formation, revealing a new pleiotropic antithrombotic pharmacological mechanism of ARBs in hypertension."

Journal • Cardiovascular • Hematological Disorders • Hypertension • Thrombosis • GPRC6A • TGFB1

M-SYFSF attenuates diabetic kidney disease by suppressing Piezo1-associated cGAS-STING signalling and tubular pyroptosis. (PubMed, Phytomedicine) - "M-SYFSF attenuated experimental DKD in association with reduced Piezo1-associated Ca²⁺ signalling, cGAS-STING activation and tubular pyroptosis-associated responses, and Piezo1 upregulation was reproducible across three rodent models and in human renal tissue. The data support an upstream contribution of Piezo1 under AGEs stress but do not establish the genetic necessity of STING, the proposed mitochondrial DNA intermediate, or the occurrence of fully executed pyroptosis."

Journal • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • CGAS • GSDMD

Racial differences on treatment response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT Trial investigators Background:Racial differences in treatment response to antihypertensive combination therapies remain uncertain.Purpose: To assess whether race modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial was a randomized, double-blind, multicenter study conducted in Brazil, comparing a novel triple single-pill (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) in patients with uncontrolled hypertension. Race does not seem to influence treatment response to single triple-pill combination therapies. The comparative treatment effect of the novel triple single-pill versus active control was consistent across racial groups, with no evidence of effect modification. These findings support the broad applicability of triple single-pill regimens across diverse racial populations."

Cardiovascular • Hypertension

Impact of baseline cardiovascular risk on hypertension treatment with a novel triple single-pill: a subanalysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT trial investigators Background: Although cardiovascular risk guides initiation of antihypertensive therapy, its influence on the response to single-pill combination regimens remains unclear.Purpose: To assess whether baseline cardiovascular risk modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial compared a novel triple single-pill combination (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) in patients with uncontrolled hypertension. Patients at low/intermediate cardiovascular risk appeared to achieve greater overall SBP reductions than those at high risk. The treatment effect of the novel triple single-pill relative to active control was consistent across cardiovascular risk strata, with no evidence of effect modification. These findings suggest that risk stratification may help..."

Cardiovascular • Hypertension

Sex differences in response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT Trial investigators Background: Further research is needed to better understand sex differences in antihypertensive response to triple single-pill combinations, particularly given the increasing use of these regimens in contemporary clinical practicePurpose: To assess whether sex modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial was a randomised, double-blind, multicenter study conducted in Brazil, comparing a novel triple single-pill combination (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) for patients with uncontrolled hypertension. Women appear to achieve greater response to antihypertensive single-pill combination therapy than men. No difference was observed regarding the treatment effect of the novel triple single-pill combination compared to the active control according..."

Cardiovascular • Hypertension

Early detection and optimal management of cardiorenal metabolic syndrome to prevent heart failure in the population with coronary heart disease: results from INTERASPIRE survey (ESC 2026) - "HF was defined as one of; clinical HF or LVEF 35pg/mL/>125pg/mL) with tiredness or shortness of breath recorded at interview. Prevention of HF requires early lifestyle intervention, risk factor control and optimal pharmacotherapy. Opportunities exist to prevent development of CRMS and/or HF. An integrated, multidisciplinary approach to manage total cardiovascular risk associated with diagnosed / undiagnosed CRMS is compelling."

Clinical • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Dyslipidemia • Heart Failure • Hypertension

Risk of incident gout and major adverse cardiovascular events according to angiotensin receptor blocker type in amlodipine-based combination therapy: a nationwide cohort study (ESC 2026) - "Among ARBs, losartan uniquely inhibits the urate transporter URAT1 in the proximal tubule, exerting a uricosuric effect, whereas valsartan, telmisartan, and olmesartan lack this property. In amlodipine-based first-line combination therapy, losartan was the only ARB associated with a reduced risk of new-onset gout, consistent with its uricosuric effect. All ARBs provided comparable MACE reduction. Losartan-based combination may offer additional benefit in mitigating gout risk among hypertensive patients."

Adverse events • Combination therapy • Cardiovascular • Hypertension • Myocardial Infarction

Glycerol-rich vesicular matrices as an effective oral platform for valsartan: Box-Behnken optimization and ex vivo/in vivo evaluation. (PubMed, J Pharm Sci) - "Finally, in vivo investigations in dexamethasone-induced hypertensive rabbits showed a significant reduction in mean arterial pressure and a two-fold increase in systemic bioavailability compared to the unprocessed medication. Consequently, the developed vesicular colloidal delivery system holds significant potential for improving valsartan's oral therapeutic delivery."

Journal • Preclinical

Valsartan-Induced Lymphocytic Gastritis: A Rare Cause of Anorexia and Weight Loss (ACG 2026) - "Figure: Figure 2. Histopathology of gastric fundus biopsy at 400x magnification showing lymphocytic gastritis."

Anorexia • Cardiovascular • Celiac Disease • Coronary Artery Disease • Gastrointestinal Disorder • Immunology • Solid Tumor

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure. (PubMed, J Am Coll Cardiol) - P3 | "In patients with HF, hemoglobin concentrations associated with the lowest risk of death and HF hospitalization were approximately 14 g/dL in women and 15 g/dL in men. Hemoglobin concentrations above WHO anemia thresholds may still carry prognostic information and, in conjunction with other clinical findings, may prompt consideration of potentially reversible contributors such as iron deficiency. (Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Added], NCT00634309; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Alternative], NCT00634400; Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Preserved], NCT00634712; A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF], NCT00232180; Irbesartan in..."

Clinical data • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders

Efforts to suppress nitrosamine formation in pharmaceuticals by reducing nitrites in excipients and hard capsules | Poster Board #1218 (ACS-Fall 2026) - "Since the detection of N-nitrosodimethylamine (NDMA), a compound recognized for its carcinogenic potential, in valsartan active pharmaceutical ingredient (API) in 2018, the contamination of nitrosamines and measures to address it have become a critical unavoidable concern in the pharmaceutical industries...Specifically, we have concluded (a) air containing NOx is always present in the manufacturing process; (b) a comprehensive assessment of each pharmaceutical product, considering the manufacturing process (API, formulation), and formulation specifications is essential; and (c) multiple countermeasures and materials are necessary to suppress the increase in nitrosamines. In this presentation, we will demonstrate the correlation between the nitrite content in excipients and capsules and the level of nitrosamine contamination, and we will also introduce various materials designed to prevent nitrosation."

Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot (clinicaltrials.gov) - P2/3 | N=50 | Recruiting | Sponsor: Jonathan Beaudoin | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular

Bifid triple viable tablets are associated with renal biochemical improvement and qualitative gastrointestinal changes in 5/6-nephrectomized rats: An exploratory microbiome-metabolome study. (PubMed, Biochim Biophys Acta Gen Subj) - "BTV was associated with reproducible renal biochemical and inflammatory improvement, qualitative gastrointestinal differences, and exploratory microbial-metabolic changes. Barrier-protein findings were nonsignificant, and small, separate cohorts preclude causal inference."

Journal • Preclinical • Chronic Kidney Disease • Gastrointestinal Disorder • Inflammation • Nephrology • Renal Disease • IL6 • OCLN • TJP1

Compound-specific effects of micropollutant-loaded gasification char on anaerobic digestion: implications for closed-loop wastewater treatment. (PubMed, J Environ Manage) - "Six compounds (benzotriazole, sulfamethoxazole, valsartan, metoprolol, carbamazepine and diclofenac) were tested in reactors containing OMP-loaded BGC, OMPs only and two reference conditions over 40 days. This difference was particularly evident for recalcitrant compound carbamazepine, suggesting that strong adsorption might be the predominant removal pathway. These findings support the closed-loop BGC system, while also highlighting the need to consider the kinetic risks of individual compounds and the fate of adsorbed OMPs during digestion."

Journal

Disarming Pseudomonas aeruginosa: repurposing vardenafil, valsartan, and olmesartan as anti-virulence and antibiofilm agents. (PubMed, Sci Rep) - "Molecular docking analyses further supported these findings, revealing favorable interactions of the tested drugs with key quorum sensing regulatory proteins. Collectively, these results highlight the anti-quorum sensing, anti-virulence, and antibiofilm potential of these repurposed drugs and suggest their possible application in topical formulations as adjunctive therapies to conventional antibiotics for managing severe pseudomonal infections."

Journal • Infectious Disease

Trace Analysis of Genotoxic Impurity 3-Amino-N-Nitrosopiperidine in Alogliptin Benzoate by Ultra-Sensitive Liquid Chromatography Tandem Mass Spectrometry. (PubMed, Biomed Chromatogr) - "In 2018 EMA and USFDA claimed the presence of N-nitrosodimethylamine in valsartan used for the treatment of hypertension. Also, spiking study was performed by the calculating percentage spiked NTPA in the drug, which ranged from 96.67% to 100.14%. The results confirmed that the methodology was reliable, precise, robust and reproducible to quantify NTPA at 1.5 ppm in samples of 2.75 mg/mL concentration."

Journal • Cardiovascular • Hypertension

Qingda Granule and Its Individual Herbs Inhibit Hypertension-Induced Vascular Smooth Muscle Cells Proliferation via ERK and JNK Pathways. (PubMed, Chin J Integr Med) - "The herbs in QDG exert significant antihypertensive effects by regulating common and unique pathways. Specifically, Unc, Scu, and Nel inhibit ERK and JNK pathway activation, which likely underlies QDG's suppression of VSMCs proliferation."

Journal • Cardiovascular • Hypertension • PCNA

Hybrid green wall - ozonation system for greywater and rainwater reclamation in a residential building: technical performance and social insights. (PubMed, J Environ Manage) - "Several OMPs, including caffeine, benzotriazole, and tramadol, were effectively removed by the green wall, while ozonation addressed more persistent compounds such as DEET or valsartan. While participants acknowledged the environmental value of water reuse, acceptance was influenced by practical concerns (odour, noise or water colour) and trust in the managing entity. Findings highlight the need to complement strong technical performance with effective communication and reliable maintenance to foster long-term adoption of such nature-based and hybrid solutions."

Journal

Identification of organic micropollutants and transformation processes in an agricultural and urban river catchment applying target and non-target analysis. (PubMed, Sci Total Environ) - "Thereby, mean concentrations of candesartan and valsartanic acid as well as the carbamazepine metabolite 10,11-dihydro-10,11-dihydroxycarbamazepine exceeded health orientation values. The exact mechanisms need to be further evaluated. The present study provides valuable insights to stressors in high modified water bodies and shows that fold change analysis after non-target data processing is a valuable tool to gain insights into transformation processes in lakes and rivers which can aid in prioritizing research in the future."

Journal

A Study on the Efficacy and Safety of Finerenone on Cardiac and Renal Function in Patients with Coronary Artery Disease and Diabetes (ChiCTR) - P4 | N=120 | Not yet recruiting | Sponsor: Pharmacy Department of Su Bei People's Hospital, Jiangsu Province; Jiangsu Provincial North Jiangsu People's Hospital

New P4 trial • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders

Clinical Observation of Adding Vitamin D to a Probucol-Based Regimen in Diabetic Nephropathy Patients. (PubMed, J Vis Exp) - "This study aimed to investigate the therapeutic efficacy of vitamin D as an adjunct to probucol-based triple therapy (valsartan + atorvastatin + probucol) in patients with diabetic nephropathy (DN) and to evaluate its impact on immune function...In conclusion, the addition of vitamin D was associated with greater clinical benefits than probucol-based triple therapy alone in this retrospective cohort of DN patients, including improvements in renal function, glucose and lipid profiles, and immune function indicators. These findings suggest that vitamin D may be a promising adjunctive agent for managing DN, but further prospective randomized controlled trials are needed to confirm causality."

Journal • Retrospective data • Diabetic Nephropathy • Immune Modulation • Immunology • Nephrology • Renal Disease • CD4 • CD8 • IL6 • TNFA

Genistein inhibits oxidative stress and alleviates vascular remodeling in hypertension through the GSK3β/FYN/Nrf2 pathway. (PubMed, Chin J Nat Med) - "In vivo, spontaneously hypertensive rats (SHR) and normotensive WKY rats got Gen (10-20 mg·kg-1·d-1) or valsartan (Val) for 10 weeks; aortic tissues were tested for morphology (HE/Masson), proliferation (PCNA), migration (MMP2/9), oxidative stress (NOX4), and VSMC phenotype (α-SMA/OPN)...Gen inhibits oxidative stress injury in the aortic tissue of SHR rats through the GSK3β/FYN/Nrf2 pathway, thereby reducing vascular remodeling in hypertension, lowering blood pressure, and exerting a protective effect on vascular lesions in hypertension. These findings provide new experimental evidence for Gen as a potential therapeutic agent against hypertensive vascular remodeling."

Journal • Cardiovascular • Fibrosis • Hypertension • Immunology • FYN • MMP2 • MMP9 • NOX4 • PCNA